These findings suggest that PPARγ expression within MG cells may be a strong candidate biomarker for identifying patient populations with aggressive breast tumours, as well as aid in predicting patients likely to benefit from novel chemotherapeutic use of PPARγ activating drugs. Here, PPARG is linked to breast neoplasm.